In Japan, Tresiba® will be available in FlexTouch®, Novo Nordisk‟s latest prefilled insulin pen, which has an easy auto-injector mechanism and in Penfill® for Novo Nordisk‟s durable insulin ...

The company expects to launch Tresiba on the completion of price negotiations in Japan, where Tresiba will be available in Novo Nordisk's insulin pens, FlexTouch and Penfill.

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW ...

ORLANDO, Florida, June 23, 2018 /PRNewswire/ -- Adults with type 2 diabetes treated with Tresiba®(insulin degludec injection)had asignificantreduc ...

Tresiba (insulin degludec) may not be safe to use while pregnant or breastfeeding. Factors including the form you take or the condition being treated may determine whether you should use the drug ...

About Tresiba® and Ryzodeg® Tresiba® is the intended brand name for insulin degludec, which is a once-daily new-generation basal insulin analogue, with an ultra-long-acting duration of action ...

Novo Nordisk presented new data on its type II diabetes drug, Tresiba at the annual meeting of the European Association for the Study of Diabetes.

Novo Nordisk announced top data from the DEVOTE trial confirming the cardiovascular safety of Tresiba (insulin degludec) vs. insulin glargine U100 when added to standard of care.. The DEVOTE trial ...

Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW ...